A new approach for developing anti-malarial agents

Drug Discovery Today

Volumn 14, Issue 19-20, 2009, Pages 999-1000

  Walker, Michael A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CHLOROQUINE; MEFLOQUINE; PIPERAQUINE; PRT 054021; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

BLOOD CLOTTING; CELL DESTRUCTION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; ENDEMIC DISEASE; ERYTHROCYTE; HUMAN; IC 50; MALARIA FALCIPARUM; MICROBIAL ACTIVITY; MULTIDRUG RESISTANCE; NONHUMAN; PARASITE SURVIVAL; PLASMODIUM FALCIPARUM; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; VENOUS THROMBOEMBOLISM;

EID: 70349319853     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.06.006     Document Type: Short Survey

References (3)

1. Kelly J.A., et al. Discovery of dual function acridones as a new antimalarial chemotype. Nature 459 (2009) 270-273
2. Martin S.K., et al. Reversal of chloroquine resistance in Plasmodium Falciparum by verapamil. Science 235 (1987) 899-901
3. Zhang P., et al. Discovery of betrixiban (PRT054021), N-(5-chloropyridinyl-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg. Med. Chem. Lett. 19 (2009) 2179-2185